A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
暂无分享,去创建一个
Yuan Wei | Thomas Jaki | Bin Cao | Jing He | Fang Qiu | Ying Liu | Hui Li | Fei Zhou | P. Horby | J. Xiang | F. Hayden | F. Zhou | Ting Yu | Guohui Fan | Zhibo Liu | Ye-ming Wang | Bin Song | Xiaoying Gu | Yuan Wei | Hui Li | Xudong Wu | Jiuyang Xu | Shengjin Tu | Yi Zhang | Hua Chen | B. Cao | Nanshan Chen | Xuan Dong | Fengyun Gong | Jingli Wang | J. Xia | T. Jaki | Dingyu Zhang | Chaolin Huang | Xing-wang Li | Xuelei Xie | Li Guo | T. Bai | Chen Wang | Yanping Cai | H. Huang | Y. Liu | Ke Wang | Shunan Ruan | Wen Liu | Chunming Jia | Frederick G Hayden | Huadong Li | Shuzhen Wang | L. Shang | Danning Wen | L. Ruan | M. Wei | Li Zhang | Caihong Li | Ye Yuan | C. Dong | Kunxia Li | Xia Zhou | Zhaohui Qu | S. Lu | Xujuan Hu | S. Luo | Jing Wu | Lu Peng | Fang Cheng | Li-juan Pan | Jun Zou | Juan Wang | Xia Liu | Qing Ge | Jingli He | Haiyan Zhan | Fang Qiu | Jing Wu | Xingwang Li | Nanshan Chen | Xuan Dong | Fengyun Gong | Jingli Wang | Ting Yu | Ke Wang | Li Guo | Tao Bai | Yeming Wang | Dingyu Zhang | Huadong Li | Shuzhen Wang | Shunan Ruan | Guohui Fan | Zhibo Liu | Xiaoying Gu | Jiuyang Xu | Lianhan Shang | Peter W Horby | Chen Wang | Danning Wen | Wen Liu | Lianguo Ruan | Bin Song | Yanping Cai | Ming Wei | Jiaan Xia | Jie Xiang | Xuelei Xie | Li Zhang | Caihong Li | Ye Yuan | Hua Chen | Hanping Huang | Shengjing Tu | Chongya Dong | Yi Zhang | Kunxia Li | Xia Zhou | Zhaohui Qu | Sixia Lu | Xujuan Hu | Shanshan Luo | Lu Peng | Fang Cheng | Lihong Pan | Jun Zou | Chunmin Jia | Juan Wang | Xia Liu | Xudong Wu | Qin Ge | Haiyan Zhan | Chaolin Huang | Hanping Huang | Juan Wang | Y. Cai | Y. Yuan | Ye Yuan | Y. Yuan | L. Pan | X. Dong | Xuan Dong | Jia’an Xia | Yanping Cai
[1] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[2] Min Kang,et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.
[3] Wei Liu,et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province , 2020, Chinese medical journal.
[4] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[5] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[6] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[7] P. Horby,et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. , 2019, The Journal of infectious diseases.
[8] M. Ison,et al. Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] Статья Редакционная. Клинические рекомендации по применению неинвазивной вентиляции легких при острой дыхательной недостаточности , 2018 .
[10] Z. Memish,et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial , 2018, Trials.
[11] Nam-Hyuk Cho,et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity , 2016, Scientific Reports.
[12] E. Won,et al. Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome , 2015, Antiviral therapy.
[13] Jian-Piao Cai,et al. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.
[14] M. Koopmans,et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen , 2014, International Journal of Antimicrobial Agents.
[15] T. Bestebroer,et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.
[16] Gokhan Metan,et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. , 2014, The Lancet. Respiratory medicine.
[17] G. Olinger,et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. , 2014, The Journal of general virology.
[18] K. To,et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus , 2013, Journal of Infection.
[19] Robert Schechter,et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] Hsuan-Cheng Huang,et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] Y. Guan,et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds , 2004, Journal of Clinical Virology.
[22] Jindrich Cinatl,et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.
[23] Y. Guan,et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.
[24] V. Wong,et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. , 2003, Hong Kong medical journal = Xianggang yi xue za zhi.